NICE publishes updated guideline on Parkinson's disease

19 July 2017

UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) today published its updated clinical guideline on Parkinson's disease.

The guideline updates some aspects of the NICE’s previous guideline on the treatment of Parkinson’s disease published in 2006. This includes the addition of a section on managing and monitoring impulse control disorders (for example, compulsive gambling, hypersexuality, binge eating and obsessive shopping) that are sometimes the result of dopaminergic therapy, a common treatment for Parkinson’s disease.

The guideline also includes new recommendations about drugs for managing motor and non-motor symptoms of Parkinson’s disease, managing Parkinson’s disease dementia, referral to occupational and speech and language therapy, and nutritional support.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK